» Articles » PMID: 30925077

Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes

Overview
Date 2019 Mar 30
PMID 30925077
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to assess the safety and performance of the Omnipod personalized model predictive control (MPC) algorithm with variable glucose setpoints and moderate intensity exercise using an investigational device in adults with type 1 diabetes (T1D). A supervised 54-h hybrid closed-loop (HCL) study was conducted in a hotel setting after a 7-day outpatient standard treatment phase. Adults aged 18-65 years with T1D and HbA1c between 6.0% and 10.0% were eligible. Subjects completed two moderate intensity exercise sessions of >30 min duration on consecutive days: the first with the glucose set point increased from 130 to 150 mg/dL and the second with a temporary basal rate of 50%, both started 90 min pre-exercise. Primary endpoints were percentage time in hypoglycemia <70 mg/dL and hyperglycemia ≥250 mg/dL. Twelve subjects participated in the study, with (mean ± standard deviation) age 36.5 ± 14.4 years, diabetes duration 21.7 ± 15.7 years, HbA1c 7.6% ± 1.1%, and total daily dose 0.60 ± 0.22 U/kg. Outcomes for the 54-h HCL period were mean glucose: 136 ± 14 mg/dL, percentage time <70 mg/dL: 1.4% ± 1.3%, 70-180 mg/dL: 85.1% ± 9.3%, and ≥250 mg/dL: 1.8% ± 2.4%. In the 12-h period after exercise start, percentage time <70 mg/dL was 1.4% ± 2.7% with the raised glucose set point and 1.6% ± 3.0% with reduced basal rate. The percentage time <70 mg/dL overnight was 0% ± 0% on both study nights. The Omnipod personalized MPC algorithm performed well and was safe during day and night use in response to variable glucose set points and with temporarily raised glucose set point or reduced basal rate 90 min in advance of moderate intensity exercise in adults with T1D.

Citing Articles

Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes.

Berget C, Sherr J, DeSalvo D, Kingman R, Stone S, Brown S Clin Diabetes. 2022; 40(2):168-184.

PMID: 35669307 PMC: 9160549. DOI: 10.2337/cd21-0083.


Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence.

Moon S, Jung I, Park C Diabetes Metab J. 2021; 45(6):813-839.

PMID: 34847641 PMC: 8640161. DOI: 10.4093/dmj.2021.0177.


Accuracy of Flash Glucose Monitoring During Postprandial Rest and Different Walking Conditions in Overweight or Obese Young Adults.

Zhang X, Sun F, Wongpipit W, Huang W, Wong S Front Physiol. 2021; 12:732751.

PMID: 34721064 PMC: 8555657. DOI: 10.3389/fphys.2021.732751.


Diabetes Technology Use in Remote Pediatric Patients with Type 1 Diabetes Using Clinic-to-Clinic Telemedicine.

Cobry E, Reznick-Lipina T, Pyle L, Slover R, Thomas J, Alonso G Diabetes Technol Ther. 2021; 24(1):67-74.

PMID: 34524007 PMC: 8783625. DOI: 10.1089/dia.2021.0229.


Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.

Brown S, Forlenza G, Bode B, Pinsker J, Levy C, Criego A Diabetes Care. 2021; 44(7):1630-1640.

PMID: 34099518 PMC: 8323171. DOI: 10.2337/dc21-0172.


References
1.
Campbell M, Walker M, Bracken R, Turner D, Stevenson E, Gonzalez J . Insulin therapy and dietary adjustments to normalize glycemia and prevent nocturnal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2015; 3(1):e000085. PMC: 4442134. DOI: 10.1136/bmjdrc-2015-000085. View

2.
Dassau E, Zisser H, Palerm C, Buckingham B, Jovanovic L, Doyle 3rd F . Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol. 2009; 2(5):863-72. PMC: 2769791. DOI: 10.1177/193229680800200518. View

3.
Turksoy K, Hajizadeh I, Hobbs N, Kilkus J, Littlejohn E, Samadi S . Multivariable Artificial Pancreas for Various Exercise Types and Intensities. Diabetes Technol Ther. 2018; 20(10):662-671. PMC: 6161329. DOI: 10.1089/dia.2018.0072. View

4.
Tsalikian E, Mauras N, Beck R, Tamborlane W, Janz K, Peter Chase H . Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005; 147(4):528-34. PMC: 2258153. DOI: 10.1016/j.jpeds.2005.04.065. View

5.
Davey R, Howe W, Paramalingam N, Ferreira L, Davis E, Fournier P . The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes. J Clin Endocrinol Metab. 2013; 98(7):2908-14. DOI: 10.1210/jc.2013-1169. View